Download presentation
Presentation is loading. Please wait.
Published byArthur Singleton Modified over 9 years ago
1
CARBOHYRATES IN CLINICAL BIOCHEMISTRY Prof. Dr. Serdar Öztezcan
2
Regulation of blood glucose concentration The concentration of glucose in the blood is regulated by a complex interplay of multiple pathways The concentration of glucose in the blood is regulated by a complex interplay of multiple pathways –Glycogenesis –Glycogenolysis –Glyconeogenesis
3
Hormones The concentration of glucose in the blood is normally maintained within a narrow interval by hormones : The concentration of glucose in the blood is normally maintained within a narrow interval by hormones : –Insulin –Counterregulatory hormones GlucagonGlucagon EpinephrineEpinephrine CortisolCortisol Growth hormoneGrowth hormone
4
Insulin Anabolic hormone Anabolic hormone –stimulates the uptake of glucose into fat and muscle –promotes the conversion of glucose to glycogen or fat for storage –inhibits glucose production by the liver –stimulates protein synthesis and inhibits protein breakdown –uptake ions (specially K + and PO 4 -3 ) The major insulin target organs are the liver, skeletal muscle and adipose tissue The major insulin target organs are the liver, skeletal muscle and adipose tissue
5
Insulin
6
Counterregulatory Hormones These hormones are catabolic These hormones are catabolic –increase hepatic glucose production initially by enhancing the breakdown of glycogen to glucose (glycogenolysis)initially by enhancing the breakdown of glycogen to glucose (glycogenolysis) later by stimulating the synthesis of glucose (glyconeogenesis)later by stimulating the synthesis of glucose (glyconeogenesis)
9
Diabetes Mellitus Dm is actually a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both Dm is actually a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both Clasification and diagnostic scheme for diabetes mellitus (ADA/WHO) Clasification and diagnostic scheme for diabetes mellitus (ADA/WHO) –Type 1 diabetes –Type 2 diabetes –Other specific types of diabetes –Gestational diabetes mellitus –Impaired Fasting Glucose –Impaired Glucose Tolerance
10
Type 1 diabetes Formerly known as IDDM or juvenile-onset diabetes Formerly known as IDDM or juvenile-onset diabetes Approximatelly 5-10% of all individuals with diabetes mellitus are in this category Approximatelly 5-10% of all individuals with diabetes mellitus are in this category Symptoms (eg. Polyuria, polydipsia, and rapid weight loss) usually present acutely Symptoms (eg. Polyuria, polydipsia, and rapid weight loss) usually present acutely Patients has insulinopenia because of loss of pancreatic islet cells Patients has insulinopenia because of loss of pancreatic islet cells Depend on insulin treatment to sustain life and prevent ketosis Depend on insulin treatment to sustain life and prevent ketosis Most individuals have antibodies that identify an autoimmun prosess Most individuals have antibodies that identify an autoimmun prosess
11
Type 2 diabetes Formerly known as NIDDM Formerly known as NIDDM This type consititues approx. 90% of all cases Patients have minimal symptoms and are not prone to ketosis This type consititues approx. 90% of all cases Patients have minimal symptoms and are not prone to ketosis Insulin concentration may be within the reference interval, decreased, or increased Insulin concentration may be within the reference interval, decreased, or increased Most people with this form of diabetes have impaired insulin action Most people with this form of diabetes have impaired insulin action Obesity is commonly associated, and weight loss alone usually improves the hyperglycemia Obesity is commonly associated, and weight loss alone usually improves the hyperglycemia Many individuals may require dietary manipulation, an oral hypoglycemic agent, or insulin terapy Many individuals may require dietary manipulation, an oral hypoglycemic agent, or insulin terapy
12
Other specific types of diabetes This subclass is associated with certain conditions such as This subclass is associated with certain conditions such as –Genetic defects of -cell function –Genetic defects in insulin action –Disease of exocrine pancreas –Endocrinopathies (e.g., Cushing disease, acromegaly, glucagonoma) –The administration of hormones and drugs known to induce -cell dysfunction (e.g., dilantine and pentamidine) or impair insulin action (e.g., glucocorticoides, thiazides, and -adrenergics) –Infections The characteristics and prognosis of this form of diabetes depends on the primary disorder The characteristics and prognosis of this form of diabetes depends on the primary disorder
13
Gestational diabetes mellitus GDM is “any degree of carbohyrates intolerance with onset or first recognation during pregnancy” GDM is “any degree of carbohyrates intolerance with onset or first recognation during pregnancy” Patient with GDM frequently return to normal postpartum Patient with GDM frequently return to normal postpartum However GDM is associated with increased perinatal complications and an increase risk for development of diabets (predominantly Type 2) in later years However GDM is associated with increased perinatal complications and an increase risk for development of diabets (predominantly Type 2) in later years
14
Impaired Fasting Glucose and Impaired Glucose Tolerance Impaired fasting glucose Impaired fasting glucose –is diagnosed in people who have a fasting glucose value above normal but below the concentration for diagnosis of diabetes –It is a metabolic stage between normal glucose homeostasis and diabetes
15
Impaired Fasting Glucose and Impaired Glucose Tolerance Impaired glucose tolerance Impaired glucose tolerance –OGTT is required to assign a patient to this class –have plasma glucose response between normal and diabetic states during the OGTT –Development of overt diabetes occurs at a rate 1-5% per year in people with IGT
16
Complications of DM Diabetic ketoacidosis Diabetic ketoacidosis –arises from a number of metabolic problems caused by insulin lack Hyperosmolar non-ketotic coma (HONK) Hyperosmolar non-ketotic coma (HONK) –occurs mostly in elderly, tip 2 diabetics –level of insulin is sufficient to prevent ketosis but does not prevent hyperglycemia and osmotic diuresis
17
Late complications of DM DM is not only characterized by the presence of hyperglycaemia but also by the occurrence of late complications DM is not only characterized by the presence of hyperglycaemia but also by the occurrence of late complications –Microangiopathy RetionopathyRetionopathy NephropathyNephropathy NeuropathyNeuropathy –Macroangiopathy AteroscleorosisAteroscleorosis
18
Diagnosis of diabetes mellitus Diagnosis depends solely on the demonstration of hyperglycemia Diagnosis depends solely on the demonstration of hyperglycemia –Diagnosis of type 1 is usually easy because hyperglycemia appears abruptly, severe, accompained by serious metabolic problemshyperglycemia appears abruptly, severe, accompained by serious metabolic problems –Diagnosis of type 2 may be difficult because the metabolic changes are often not severe enough for the patient to notice symptomsthe metabolic changes are often not severe enough for the patient to notice symptoms Complications are present in approximately 30% of patients at clinical diagnosis of type 2 diabetsComplications are present in approximately 30% of patients at clinical diagnosis of type 2 diabets
19
Diagnosis of diabetes mellitus All adults older than age 45 years should have a measurement of fasting blood glucose every 3 years All adults older than age 45 years should have a measurement of fasting blood glucose every 3 years Earlier age or more frequently in individuals who display; Earlier age or more frequently in individuals who display; –Obesity (BMI of 27 kg/m 2 ) –Family history of diabetes in a first-degree relative –History of GDM or delivering a baby > 4.1 kg –Hypertension (> 140/90 mm Hg) –Low HDL concentration (< 35mg/dL) –Elevated triglyceride concentrations (> 250 mg/dL) –A history of IGF or OGT
20
Criteria for the diagnosis of diabetes mellitus Any one of the following methods is diagnostic; Any one of the following methods is diagnostic; –Classic symptoms of diabetes + causal/random plasma glucose concentration > 200 mg/dL –Fasting plasma glucose > 126 mg/dL –Two-hour plasma glucose > 200 mg/dL during the OGTT * If, any three criteria is positive, it must be confirmed on a subsequent day by any of the three methods
21
Criteria for the diagnosis of diabetes mellitus Intermediate group Intermediate group –Impaired Fasting Glucose Fasting plasma glucose between 100 (106) and 125 mg/dL.Fasting plasma glucose between 100 (106) and 125 mg/dL. –Impaired Glucose Tolerance Fasting plasma glucose < 126 mg/dLFasting plasma glucose < 126 mg/dL Two-hour OGTT plasma glucose concentration is between 140 and 199 mg/dLTwo-hour OGTT plasma glucose concentration is between 140 and 199 mg/dL
22
Oral glucose tolerance test (OGTT) In OGTT plasma glucose concentrations are measured fasting, then every 30 minutes for 2 hours after an oral glucose load In OGTT plasma glucose concentrations are measured fasting, then every 30 minutes for 2 hours after an oral glucose load Although more sensitive than FPG determinations, OGTT is affected by a large number of factors that result in poor reproducibility Although more sensitive than FPG determinations, OGTT is affected by a large number of factors that result in poor reproducibility
23
Oral glucose tolerance test (OGTT) The following conditions should be met for performing an OGTT ; The following conditions should be met for performing an OGTT ; –discontinue, when possible, medications known to affect it (thiazides, oc, corticosteroids) –in the morning after 3 days of unrestricted diet (150 g ch/day) and activity –after a 10-14 hour fast –seated during the test without smoking cigarettes and drinking coffee ect. –For nonpregnant adults 75 g, –for children 1.75 g/kg (max 75g ), –dissolved in 300 ml water / 5 minutes
24
Diagnosis of GDM ADA recommentation for laboratory diagnosis of GDM are ADA recommentation for laboratory diagnosis of GDM are –Low-risk patients require no testing –Average-risk patients should be testing at 24 to 28 weeks of gestation –High-risk patients should undergo immediate testing
25
Diagnosis of GDM Risk factors for GDM include, Risk factors for GDM include, –Family history of DM in a first-degree relative –Obesity –Advanced maternal age –Glycosuria –History of poor obstetric outcome (stillbirth or macrosomia) –Member of an ethnic group with a high prevalence of GDM
26
Diagnosis of GDM First step is identical to that for diagnose diabetes in a nonpregnant individual (Fasting >126 or random >200) First step is identical to that for diagnose diabetes in a nonpregnant individual (Fasting >126 or random >200) However, in the absence of that degree of hyperglycemia, average and high risk patients receive a glucose tolerance test following one of two methods; However, in the absence of that degree of hyperglycemia, average and high risk patients receive a glucose tolerance test following one of two methods; –One step test –Two step test
27
Diagnosis of GDM One step test ; perform a 100 g OGTT for 3 hour (or 75 g for 2 hour - it is not as well validated as the 100 g test) One step test ; perform a 100 g OGTT for 3 hour (or 75 g for 2 hour - it is not as well validated as the 100 g test) Two step test ; the first step is a 50 g oral glucose load (the patient does not need to be fasting) followed by a plasma glucose determination at 1 hour Two step test ; the first step is a 50 g oral glucose load (the patient does not need to be fasting) followed by a plasma glucose determination at 1 hour –A value grater than or equal to 140 mg /dL (or 130) indicates the necessity for definive testing (one step test) 90%-130, 80% 14090%-130, 80% 140
28
Diagnosis of GDM To diagnose GDM with 100 g test at least two values must meet or exceed the following, To diagnose GDM with 100 g test at least two values must meet or exceed the following, –Fasting95mg/dL –1 hr180mg/dL –2 hr155mg/dL –3 hr140mg/dL
29
Gestational diabetes mellitus At 6 to 12 weeks postpartum, all patients who had GMD should be evaluated for diabetes At 6 to 12 weeks postpartum, all patients who had GMD should be evaluated for diabetes if not present, be reevaluated for diabetes at least every 3 years if not present, be reevaluated for diabetes at least every 3 years
30
Infants born to mothers with diabetes Infants born to mothers with diabetes are increased risk for respiratuary distress syndrome, hypocalcemia and, hyperbilirubinemia Infants born to mothers with diabetes are increased risk for respiratuary distress syndrome, hypocalcemia and, hyperbilirubinemia Fetal insulin secretion is stimulated in the neonate of mother with diabetes. When the infant is born and the umblical cord is severed, the infant’s oversupply of glucose is abruptly terminated, causing severe hypoglycemia Fetal insulin secretion is stimulated in the neonate of mother with diabetes. When the infant is born and the umblical cord is severed, the infant’s oversupply of glucose is abruptly terminated, causing severe hypoglycemia
31
Hypoglycemia Hypoglycemia involves decreased plasma glucose levels and can have many causes Hypoglycemia involves decreased plasma glucose levels and can have many causes –Some are transient and relatively insignificant –Others can be life threating Glucagon and other glycemic factors are released is between 65-70 mg/dL Glucagon and other glycemic factors are released is between 65-70 mg/dL Symptoms of hypoglycemia appear at about 50-55 mg/dL Symptoms of hypoglycemia appear at about 50-55 mg/dL
32
Hypoglycemia Hypoglycemia was classified as Hypoglycemia was classified as –postabsorbative (fasting) –postprandial (reactive) Current approaches suggest classification based on clinical characteristics. This classification separates patients into those who appear healthy or sick Current approaches suggest classification based on clinical characteristics. This classification separates patients into those who appear healthy or sick
33
Hypoglycemia Symptoms of hypoglycemia may be categorized as neurogenic (adrenergic) or neuroglycopenic Symptoms of hypoglycemia may be categorized as neurogenic (adrenergic) or neuroglycopenic –Neurogenic symptoms include sweating, shakiness, tachycardia, and anxiety –Neuroglycopenic symptoms include weakness, tiredness, or dizziness; difficulty with concentration; confusion; blurred vision; and, in extreme cases, coma and death
34
Hypoglycemia Some of causes of hypoglycemia Some of causes of hypoglycemia –Drugs (insulin, oral ) and ethanol –Insulinoma –Severe exercise –Glucogen storage diseases: Glucose 6-phospathase deficiency tip 1 (von Gierke)Glucose 6-phospathase deficiency tip 1 (von Gierke) –Neonatal hypoglycemia –Galactosemia –Hormonal deficiencies - cortisol, growth hormone (in children), glucagon, and epinephrine –Critical illnesses - cardiac, hepatic, and renal diseases, sepsis –Congenital - carnitine deficiency
35
Role of laboratory Glucose measurement Glucose measurement –Serum or plasma glucose concentration –Self-monitoring of whole blood glucose concentrations (capillary) –Urine ( Treshold 170-180 mg/dL ) Glucose tolerance tests Glucose tolerance tests Glycosylated hemoglobine Glycosylated hemoglobine Ketones Ketones Microalbuminuria Microalbuminuria Islet autoantibody Islet autoantibody Insulin Insulin
36
Glycosylated hemoglobine Long term blood glucose regulation can be followed by measurement of glycosylated hemoglobine Long term blood glucose regulation can be followed by measurement of glycosylated hemoglobine Formation of a hemoglobin compound when glucose reacts with the amino group of hemoglobin Formation of a hemoglobin compound when glucose reacts with the amino group of hemoglobin The rate of formation is directly proportional to the plasma glucose concentrations The rate of formation is directly proportional to the plasma glucose concentrations Reflects the avarage blood glucose level over the previous 2-3 months Reflects the avarage blood glucose level over the previous 2-3 months Hemoglobin A1c the most common Hemoglobin A1c the most common Reference values 4,5 to 6% (> 6,5 diagnose ?) Reference values 4,5 to 6% (> 6,5 diagnose ?) %1 --- 35mg/dL %1 --- 35mg/dL
37
Fructosamine Refers to the ketoamin linkage between glucose and protein Refers to the ketoamin linkage between glucose and protein Since all serum protein can be glycated and albumin is the most abundant protein in serum, measurement of fructosamin is largely a measurement of albumin Since all serum protein can be glycated and albumin is the most abundant protein in serum, measurement of fructosamin is largely a measurement of albumin Measure of glycemic control during the 3-week period before sampling, since the half-life of albumin is 2 to 3 weeks Measure of glycemic control during the 3-week period before sampling, since the half-life of albumin is 2 to 3 weeks
38
Ketones Ketone bodies are produced by the liver through metabolism of fatty acid to provide a ready energy source from stored lipids at times of low carbohyrate availability such as Ketone bodies are produced by the liver through metabolism of fatty acid to provide a ready energy source from stored lipids at times of low carbohyrate availability such as –diabetes mellitus, starvation/fasting, high-fat diets, prolonged vomiting, and glycogen storage disease The three ketone bodies are The three ketone bodies are – aceton (2%), – acetoacetic acid (20%), – -hidroxybutyric acid (78%) Recommended for patients with type 1 diabetes during Recommended for patients with type 1 diabetes during –acute illness, stress, pregnancy, eleveted blood glucose above 300 mg/dL or when patient has sings of ketoacidosis
39
Microalbuminuria Diabetes mellitus causes progressive changes to the kidneys and ultimately results in diabetic nephropathy Diabetes mellitus causes progressive changes to the kidneys and ultimately results in diabetic nephropathy This complication progesses over years and may be delayed by aggresive glycemic control This complication progesses over years and may be delayed by aggresive glycemic control An early sign is an increase in urinary albumine An early sign is an increase in urinary albumine Microalbumin measurements are useful to assist in diagnosis at an early stage and before the development of proteinuria Microalbumin measurements are useful to assist in diagnosis at an early stage and before the development of proteinuria Microalbumin 30-300 mg/day (reference interval <30 mg/day) Microalbumin 30-300 mg/day (reference interval <30 mg/day) Proteinuria; greater than 0,3/0,5 g/day Proteinuria; greater than 0,3/0,5 g/day
40
Islet autoantibody and insulin Islet autoantibody Islet autoantibody –The presence of autoantibodies to the cells of the pancreas is charactheristic of type 1 –Testing is not currently recommended for rutine screening for diabetes diagnosis –In the future, it might identify at-risk, prediabetik patients Insulin Insulin –Not required for the diagnosis of diabetes mellitus –Insulin resistance –However, ın certain hypoglycemic states, it is important to know the concentration of insulin in relation to the plasma glucose concentration -insulinoma
41
HOMA-IR The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta-cell function The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta-cell function It was first described under the name HOMA by Matthews et al. in 1985 It was first described under the name HOMA by Matthews et al. in 1985 Glucose X Insulin X 0,055 : <2.3 Glucose X Insulin X 0,055 : <2.3 22.5 22.5
42
Case study Fasting glucose 95 Fasting glucose 95 Fasting glucose 135 Fasting glucose 135 Fasting glucose 115 Fasting glucose 115 Random glucose 202 Random glucose 202 OGTT 2 hour 145 OGTT 2 hour 145 OGTT 2 hour 207 OGTT 2 hour 207 Serial measurement Serial measurement –1. quarter HbA1c 7.8% FPG 280 –2. quarter HbA1c 15.3% FPG 85 –3. quarter HbA1c 8.5% FPG 91 Two test Two test –Self monitoring 200 –In the laboratory with serum
Similar presentations
© 2025 SlidePlayer.com Inc.
All rights reserved.